S Carlsson

Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis

A Jawaid, E M Brown, L R Cardon, 2008, The Pharmacogenomics Journal.

The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects.

A Abrahamsson, U Bredberg, U. Bredberg, 2001, Thrombosis research.